News for Rocket Pharmaceuticals, Inc. (RCKT)

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (”œRocket” or the

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuti

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (”œRocket” or the

Rocket Pharmaceuticals (RCKT) has received a revised analyst rating from Canaccord Genuity, maintaining its "Buy" status. However, the price target has been sig

Canaccord has revised its price target for Rocket Pharmaceuticals (RCKT), reducing it from $34 to $11, while maintaining a Buy rating on the stock. This adjustm

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (”œRocket” or the

PR NewswireNEW YORK, June 1, 2025 NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceut

Rocket Pharmaceuticals (RCKT) was downgraded by Evercore ISI from "Outperform" to "In Line," with its price target significantly reduced from $18 to $5. This do

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (”œRocket” or the

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping more than 600 points on Tuesday. President Donald Trump announced the extensi...

U.S. equities took off at midday on word President Donald Trump was delaying new tariffs on European Union imports.

U.S. stocks traded higher this morning, with the Nasdaq Composite surging more than 300 points on Tuesday. President Donald Trump announced the extension of the...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

PR NewswireROCKVILLE, Md., May 19, 2025 $150 million secured at closing extends cash runway into early 2027REGENXBIO retains additional potential non-dilut

On May 12, 2025, Scotiabank analyst Greg Harrison released an update regarding Rocket Pharmaceuticals (RCKT). The analyst maintained a "Sector Outperform" ratin

Scotiabank has revised its price target for Rocket Pharmaceuticals (RCKT), decreasing it from $52 to $51 while maintaining an Outperform rating for the shares.

Canaccord analyst Whitney Ijem has adjusted the price target for Rocket Pharmaceuticals (RCKT), reducing it from $36 to $34, while maintaining a Buy rating for

On May 9, 2025, Chardan Capital's analyst, Geulah Livshits, revised the price target for Rocket Pharmaceuticals (RCKT), adjusting it downward from $54.00 to $45